Eli Lilly to discontinue four unprofitable insulin drugs

Eli Lilly will remove four insulin drugs with low or falling sales from the U.S. market, including its remaining animal-based insulins. Biosynthetic insulins began replacing animal insulins in 1983. Two percent of the 3.5 million insulin users in the U.S. depend on these products and will have until the end of the year to find replacements. The discontinued products make up a small percentage of the company's total insulin sales of more than $2 billion a year.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI